Drug intelligence / Profile preview

Nanozyme-D

Development stage: Unknown
Lead developer: Cenyx Biotech
Modality: Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

Nanozyme-D is a therapeutic candidate currently in the development pipeline of Cenyx Biotech. It belongs to the company's proprietary "Nanozyme" platform, which involves the development of nanomaterials that exhibit enzyme-like activities, such as mimicking superoxide dismutase or catalase to modulate oxidative stress. As of the latest company disclosures, the specific chemical composition, biological targets, and therapeutic indications for Nanozyme-D are classified as confidential.

Beyond the preview

Go deeper on Nanozyme-D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanozyme-D.

Explore the full profile